Company Description
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals.
The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals.
It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system.
The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020.
Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
| Country | United States |
| IPO Date | Nov 21, 2017 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 144 |
| CEO | Larry C. Heaton II |
Contact Details
Address: 100 Phoenix Drive Ann Arbor, Michigan United States | |
| Website | https://www.zomedica.com |
Stock Details
| Ticker Symbol | ZOM |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001684144 |
| CUSIP Number | 98980M109 |
| ISIN Number | CA98980M1095 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Larry C. Heaton II | President, Chief Executive Officer & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 03, 2025 | 4 | Filing |
| Jan 03, 2025 | 3 | Filing |
| Dec 19, 2024 | 8-K | Current Report |
| Nov 26, 2024 | 4/A | [Amend] Filing |
| Nov 19, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 4 | Filing |
| Nov 13, 2024 | 4 | Filing |
| Nov 13, 2024 | 4 | Filing |
| Nov 13, 2024 | 4 | Filing |
| Nov 13, 2024 | 4 | Filing |